[
    [
        {
            "time": "2022-11-11",
            "original_text": "凯莱英11月11日大宗交易成交208.54万元",
            "features": {
                "keywords": [
                    "凯莱英",
                    "大宗交易",
                    "成交额"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药生物"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "凯莱英11月11日大宗交易成交208.54万元",
                "Correlation": 9,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 6,
                "Duration": 4,
                "Entity_Density": 8,
                "Market_Scope": 3,
                "Time_Proximity": 9,
                "Headline_Structure": 6,
                "Source_Recency": 9
            }
        },
        {
            "time": "2022-11-11",
            "original_text": "A股共发生201宗大宗交易成交45.76亿元（11月11日）",
            "features": {
                "keywords": [
                    "A股",
                    "大宗交易",
                    "总成交额"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "A股共发生201宗大宗交易成交45.76亿元（11月11日）",
                "Correlation": 4,
                "Sentiment": 5,
                "Importance": 5,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 3,
                "Market_Scope": 8,
                "Time_Proximity": 9,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "2022-11-11",
            "original_text": "凯莱英现1笔大宗交易 共成交208.54万元",
            "features": {
                "keywords": [
                    "凯莱英",
                    "大宗交易",
                    "单笔成交"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药生物"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "凯莱英现1笔大宗交易 共成交208.54万元",
                "Correlation": 9,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 6,
                "Duration": 4,
                "Entity_Density": 9,
                "Market_Scope": 3,
                "Time_Proximity": 9,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "2022-11-11",
            "original_text": "凯莱英今日大宗交易成交0.51万股，成交价408.9元溢价0.0%",
            "features": {
                "keywords": [
                    "凯莱英",
                    "大宗交易",
                    "成交量",
                    "成交价",
                    "溢价率"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药生物"
                ],
                "causal_factor": "true",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "凯莱英今日大宗交易成交0.51万股，成交价408.9元溢价0.0%",
                "Correlation": 10,
                "Sentiment": 5,
                "Importance": 7,
                "Impact": 7,
                "Duration": 5,
                "Entity_Density": 10,
                "Market_Scope": 2,
                "Time_Proximity": 10,
                "Headline_Structure": 8,
                "Source_Recency": 10
            }
        },
        {
            "time": "2022-11-11",
            "original_text": "医药生物行业《关于推动原料药产业高质量发展实施方案的通知》政策点评：提升产业全球竞争力 API板块性价比凸显",
            "features": {
                "keywords": [
                    "医药生物",
                    "政策",
                    "原料药",
                    "高质量发展",
                    "全球竞争力",
                    "API板块"
                ],
                "sentiment_score": 0.9,
                "policy_related": "true",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药生物"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "医药生物行业《关于推动原料药产业高质量发展实施方案的通知》政策点评：提升产业全球竞争力 API板块性价比凸显",
                "Correlation": 6,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 8,
                "Entity_Density": 5,
                "Market_Scope": 9,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "2022-11-11",
            "original_text": "21健讯Daily｜未接种新冠疫苗重症和死亡几率高15倍；凯莱英即将在港二次上市",
            "features": {
                "keywords": [
                    "新冠疫苗",
                    "重症",
                    "死亡率",
                    "凯莱英",
                    "港股二次上市"
                ],
                "sentiment_score": 0.3,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药生物"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "21健讯Daily｜未接种新冠疫苗重症和死亡几率高15倍；凯莱英即将在港二次上市",
                "Correlation": 8,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 7,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        }
    ]
]